Logo

Merck Reports Improved Overall Survival Results of Keytruda (pembrolizumab) vs Chemotherapy in KEYNOTE-181 Study

Share this

Merck Reports Improved Overall Survival Results of Keytruda (pembrolizumab) vs Chemotherapy in KEYNOTE-181 Study

 Shots:

  • The P-III KEYNOTE-181 study involves assessing of Keytruda monothx vs CT in 600 patients in ratio (1:1) receiving (Keytruda 200 mg FD q3w) or IV CT (docetaxel /paclitaxel/ irinotecan) in patients with 2L advanced or metastatic esophageal or esophagogastric junction carcinoma
  • The study has shown improved results of OS in patients with CPS ≥10- no new safety signals were observed
  • Keytruda is a mAb serving as an anti-PD-1 therapy for the tumor cells blocking the interaction between PD-1 and its ligands- PD-L1 and PD-L2 and is currently studied in 850+ trials globally

Ref: Merck | Image: Merck 


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions